MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma

Journal of Experimental & Clinical Cancer Research

Xiuheng Liu¹  Min Wang¹  Jia Guo¹ 

[1] Department of Urology, Renmin Hospital of Wuhan University, Wuhan University, Jiefang Road 238, Wuhan 430060, Hubei, People’s Republic of China

关键词: BCOX1;    Prostate cancer;    miR-195;    Metastasis;    miRNA;   

Others  :  1226277
DOI  :  10.1186/s13046-015-0209-7

 received in 2015-06-16, accepted in 2015-08-20,  发布年份 2015

【 摘 要 】

Elucidation of the downstream targets regulated by the metastasis-suppressive miRNAs can shed light on the metastatic processes in prostate cancer (PCa). We conducted microarray analyses and found that miR-195 was significantly decreased in metastatic PCa. Low miR-195 expression is an independent prognostic factor for poor biochemical recurrence-free and overall survival. Forced expression of miR-195 in PCa cells drastically inhibits proliferation, migration and invasion in vitro and inhibits tumor growth and metastasis in vivo. BCOX1 is identified as a direct target of miR-195 in PCa, and is found to be drastically increased in metastatic PCa. BCOX1 knockdown phenotypically copies miR-195-induced phenotypes, whereas forced expression of BCOX1 reverses the effects of miR-195. Collectively, this is the first report unveils that loss of miR-195 expression and thus uncontrolled BCOX1 upregulation might drive PCa metastasis.

【 授权许可】

   
2015 Guo et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
• [2]Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6(4):259-69.
• [3]Bushati N, Cohen SM: microRNA functions. Annu Rev Cell Dev Biol 2007, 23:175-205.
• [4]Carthew RW, Sontheimer EJ: Origins and Mechanisms of miRNAs and siRNAs. Cell 2009, 136(4):642-55.
• [5]Slack FJ, Weidhaas JB: MicroRNA in cancer prognosis. N Engl J Med 2008, 359:2720-2.
• [6]Zhang H, Wei Q, Liu R, Qi S, Liang P, Qi C, Wang A, Sheng B, Li L, Xu Y: Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer. PLoS One 2014, 9(3):e91069.
• [7]Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, Xu Y: Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. J Exp Clin Cancer Res 2013, 32:77. BioMed Central Full Text
• [8]Kim J, Yu W, Kovalski K, Ossowski L: Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998, 94:353-62.
• [9]Watahiki A, Wang Y, Morris J, Dennis K, O’Dwyer HM, Gleave M, Gout PW, Wang Y: MicroRNAs associated with metastatic prostate cancer. PLoS One 2011, 6(9):e24950.
• [10]Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11-22.
• [11]LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL: Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002, 62(15):4499-506.
• [12]Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D’Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002, 1(2):203-9.
• [13]Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S: Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008, 68(3):927-36.
• [14]Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH: Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004, 22(14):2790-9.
• [15]Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL: Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004, 164(1):217-27.
• [16]Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL: Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004, 113(6):913-23.
• [17]Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR, Rubin MA: Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008, 100(11):815-25.15.
• [18]Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S: Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008, 68(3):927-36.
• [19]Cai C, Chen QB, Han ZD, Zhang YQ, He HC, Chen JH, et al. miR-195 inhibits tumor progression by targeting RPS6KB1 in human prostate cancer. Clin Cancer Res. 0217.2015.
• [20]Liu B, Qu J, Xu F, Guo Y, Wang Y, Yu H, Qian B: MiR-195 suppresses non-small cell lung cancer by targeting CHEK1. Oncotarget 2015, 6(11):9445-56.
• [21]Jain M, Zhang L, Boufraqech M, Liu-Chittenden Y, Bussey K, Demeure MJ, Wu X, Su L, Pacak K, Stratakis CA, Kebebew E: ZNF367 inhibits cancer progression and is targeted by miR-195. PLoS One 2014, 9(7):e101423.
• [22]Guo H, Li W, Zheng T, Liu Z: MiR-195 targets HDGF to inhibit proliferation and invasion of NSCLC cells. Tumour Biol 2014, 35(9):8861-6.
• [23]Yongchun Z, Linwei T, Xicai W, Lianhua Y, Guangqiang Z, Ming Y, Guanjian L, Yujie L, Yunchao H: MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB. Cancer Lett 2014, 347(1):65-74.
• [24]Merola R, Tomao L, Antenucci A, Sperduti I, Sentinelli S, Masi S, Mandoj C, Orlandi G, Papalia R, Guaglianone S, Costantini M, Cusumano G, Cigliana G, Ascenzi P, Gallucci M, Conti L: PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. J Exp Clin Cancer Res 2015, 34:15. BioMed Central Full Text
• [25]Tsaur I, Thurn K, Juengel E, Gust KM, Borgmann H, Mager R, Bartsch G, Oppermann E, Ackermann H, Nelson K, Haferkamp A, Blaheta RA: sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients. J Exp Clin Cancer Res 2015, 34:43. BioMed Central Full Text
• [26]Jilg CA, Ketscher A, Metzger E, Hummel B, Willmann D, Rüsseler V, Drendel V, Imhof A, Jung M, Franz H, Hölz S, Krönig M, Müller JM, Schüle R: PRK1/PKN1 controls migration and metastasis of androgen-independent prostate cancer cells. Oncotarget 2014, 5(24):12646-64.
• [27]Vicente CM, Lima MA, Nader HB, Toma L: SULF2 overexpression positively regulates tumorigenicity of human prostate cancer cells. J Exp Clin Cancer Res 2015, 34:25. BioMed Central Full Text
• [28]De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E, Fabbri F, Carretta E, Amadori D, Paganelli G, Matteucci F: Early outcome prediction on 18 F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget 2014, 5(23):12448-58.
• [29]Sofra M, Antenucci A, Gallucci M, Mandoj C, Papalia R, Claroni C, Monteferrante I, Torregiani G, Gianaroli V, Sperduti I, Tomao L, Forastiere E: Perioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques. J Exp Clin Cancer Res 2014, 33:63. BioMed Central Full Text
• [30]Zhang H, Qi C, Li L, Luo F, Xu Y: Clinical significance of NUCB2 mRNA expression in prostate cancer. J Exp Clin Cancer Res 2013, 32(1):56. BioMed Central Full Text
• [31]Chiang YT, Wang K, Fazli L, Qi RZ, Gleave ME, Collins CC, Gout PW, Wang Y: GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget 2014, 5(2):451-61.
• [32]He JH, Zhang JZ, Han ZP, Wang L, Lv YB, Li YG: Reciprocal regulation of PCGEM1 and miR-145 promote proliferation of LNCaP prostate cancer cells. J Exp Clin Cancer Res 2014, 33:72. BioMed Central Full Text
• [33]Tang X, Mahajan SS, Nguyen LT, Béliveau F, Leduc R, Simon JA, Vasioukhin V: Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget 2014, 5(5):1352-62.
• [34]Crea F, Watahiki A, Quagliata L, Xue H, Pikor L, Parolia A, Wang Y, Lin D, Lam WL, Farrar WL, Isogai T, Morant R, Castori-Eppenberger S, Chi KN, Wang Y, Helgason CD: Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget 2014, 5(3):764-74.
• [35]Zhang H, Cheng S, Wang A, Ma H, Yao B, Qi C, Liu R, Qi S, Xu Y: Expression of RABEX-5 and its clinical significance in prostate cancer. J Exp Clin Cancer Res 2014, 33:31. BioMed Central Full Text
• [36]Zhang H, Qi S, Zhang T, Wang A, Liu R, Guo J, Wang Y, Xu Y: miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget 2015, 6(8):6092-104.
• [37]Li J, Xiang S, Zhang Q, Wu J, Tang Q, Zhou J, Yang L, Chen Z, Hann SS: Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independentprostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C. J Exp Clin Cancer Res 2015, 34:46. BioMed Central Full Text
• [38]Xiang YZ, Xiong H, Cui ZL, Jiang SB, Xia QH, Zhao Y, Li GB, Jin XB: The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res 2013, 32:9. BioMed Central Full Text
• [39]Xiang J, Bian C, Wang H, Huang S, Wu D: MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion inprostate cancer. J Exp Clin Cancer Res 2015, 34:8. BioMed Central Full Text
• [40]Goto Y, Kojima S, Nishikawa R, Enokida H, Chiyomaru T, Kinoshita T, Nakagawa M, Naya Y, Ichikawa T, Seki N: The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget 2014, 5(17):7748-59.
• [41]Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL, Huebner K: microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 2014, 5(5):1174-84.
• [42]Neeb A, Hefele S, Bormann S, Parson W, Adams F, Wolf P, Miernik A, Schoenthaler M, Kroenig M, Wilhelm K, Schultze-Seemann W, Nestel S, Schaefer G, et al.: Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer. Oncotarget 2014, 5(18):8681-9.
• [43]Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, et al.: Serum microRNA expression patterns that predict early treatment failure in prostate cancerpatients. Oncotarget 2014, 5(3):824-40.
• [44]Song J, Yang W, Shih IM, Zhang Z, Bai J: Identification of BCOX1, a novel gene overexpressed in breast cancer. Biochim Biophys Acta 2006, 1760(1):62-9.
• [45]Liu T, Zhang XY, He XH, Geng JS, Liu Y, Kong DJ, Shi QY, Liu F, Wei W, Pang D: High levels of BCOX1 expression are associated with poor prognosis in patients with invasive ductal carcinomas of the breast. PLoS One 2014, 9(1):e86952.